2026-07-22T20:10:51Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/139842024-11-29T12:15:27Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16988

00925njm 22002777a 4500 dc Salvador, Fernando author Lucas-Dato, Ana author Roure, Silvia author Arsuaga, Marta author Pérez-Jacoiste, Asunción author García-Rodríguez, Magdalena author Pérez-Molina, José A author Buonfrate, Dora author Saugar, Jose Maria author Molina, Israel author 2021-06-27 Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients. Pathogens. 2021;10(7):812. 10.3390/pathogens10070812 2076-0817 Pathogens (Basel, Switzerland) 34199000 http://hdl.handle.net/20.500.12105/13984 PCR Strongyloides stercoralis Immunosuppression Ivermectin Population pharmacokinetics Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol